| 1 |
33290594 | Outcome of patients hospitalized for Covid-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: Results of the ACECoV study. | 2021 Feb |
1 |
| 2 |
33426364 | Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment. | 2021 Mar |
2 |
| 3 |
33475077 | COVID-19, Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Inhibition: Implications for Practice. | 2021 Jan 20 |
1 |
| 4 |
33768439 | The Renin-Angiotensin System, Hypertension, and SARS-CoV-2 Infection: a Review. | 2021 Mar 25 |
2 |
| 5 |
32311651 | Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic. | 2020 Jul - Aug |
2 |
| 6 |
32611305 | Overview of Covid-19 Regarding the Cardiovascular Situation in the Light of Current Reports. | 2020 |
1 |
| 7 |
32665962 | The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19. | 2020 Sep 11 |
1 |
| 8 |
32712300 | The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future. | 2020 Sep 15 |
2 |